Cancer News
OncoLink Cancer News - HealthDay

Follow-Up Biopsies in Celiac Disease Help ID Lymphoma Risk

Monday, August 5, 2013 (Last Updated: 08/06/2013)

MONDAY, Aug. 5 (HealthDay News) -- Patients with celiac disease (CD) who have intestinal biopsy showing persistent villous atrophy are at increased risk for lymphoproliferative malignancy (LPM), according to research published in the Aug. 6 issue of the Annals of Internal Medicine.

Benjamin Lebwohl, M.D., of the Columbia University College of Physicians and Surgeons in New York City, and colleagues conducted a population-based cohort study to assess the association between mucosal healing or damage on intestinal biopsy in CD and risk for LPM.

The researchers found that, of 7,625 patients with CD who had follow-up intestinal biopsy after initial diagnosis, 3,308 patients (43 percent) had persistent villous atrophy. Patients with persistent villous atrophy had a higher rate of LPM (standardized incidence ratio [SIR], 3.78) than those with mucosal healing (SIR, 1.50) or that expected in the general population (SIR, 2.81). Compared with those with mucosal healing, CD patients with persistent villous atrophy were at increased risk for LPM (hazard ratio [HR], 2.26).

"Follow-up biopsies may be useful in identifying patients with CD at increased risk for LPM," the authors write.

Full Text (subscription or payment may be required)

Specialties Pediatrics
Family Practice

Health News Copyright © 2013 HealthDay. All rights reserved.

I Wish You Knew

Benefits of yoga during cancer treatment

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More